Results 211 – 220 of 250 for Enhertu (0.05 seconds)

Imfinzi approved in the US for extensive-stage small cell lung cancer

kinase, along with other potential new medicines. Enhertu (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate is in development for ...

Imfinzi confirmed a sustained overall survival benefit in final analysis of the Phase III CASPIAN trial in 1st-line extensive-stage small cell lung cancer

kinase, along with other potential new medicines. Enhertu (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate is in development for ...

Imfinzi approved in the US for less-frequent, fixed-dose use

medicines from the early-stage pipeline, including Enhertu (trastuzumab deruxtecan). AstraZeneca’s approach to IO IO is a therapeutic approach ...

Imfinzi approved in the EU for the treatment of extensive-stage small cell lung cancer

medicines from the early-stage pipeline, including Enhertu. AstraZeneca’s approach to IO IO is a therapeutic approach designed to stimulate the ...

Imfinzi combined with novel immunotherapies improved clinical outcomes for patients with unresectable, Stage III non-small cell lung cancer

and Iressa (gefitinib); Imfinzi and tremelimumab; Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan in collaboration with Daiichi Sankyo; ...

Imfinzi approved in China for the treatment of extensive-stage small cell lung cancer

(gefitinib); Imfinzi (durvalumab) and tremelimumab; Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan in collaboration with Daiichi Sankyo; ...

Imfinzi and tremelimumab with chemotherapy improved progression-free survival by 28% and overall survival by 23% in 1st-line Stage IV non-small cell lung cancer vs. chemotherapy

(gefitinib); Imfinzi (durvalumab) and tremelimumab; Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan in collaboration with Daiichi Sankyo; ...

Orpathys approved in China for patients with lung cancer and MET gene alterations

(gefitinib); Imfinzi (durvalumab) and tremelimumab; Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan in collaboration with Daiichi Sankyo; ...

Imfinzi approved in the EU for less-frequent, fixed-dose use in unresectable non-small cell lung cancer

medicines from the early-stage pipeline including Enhertu (trastuzumab deruxtecan). AstraZeneca in immunotherapy Immunotherapy is a ...

Tagrisso approved in China for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer

medicines include Tagrisso, Imfinzi (durvalumab), Enhertu (trastuzumab deruxtecan), datopotamab deruxtecan and savolitinib. AstraZeneca in oncology ...

Previous 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 Next